OncRef

Clinical Trial: NCT03751436

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Roswell Park Cancer Institute
Information Provided By:Roswell Park Cancer Institute
Last Update Posted:2023-10-16

Study Overview

Brief Summary

This phase Ib/II trial studies the side effects and best dose of venetoclax when given together with enzalutamide and to see how well they work in treating patients with castration resistant prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgens made by the body. Venetoclax may target a special group of prostate cancer cells that is known to lead to resistance to treatment. Giving enzalutamide and venetoclax may work better in treating patients with castration resistant prostate cancer.

Official Title

Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Conditions

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8

Intervention / Treatment

  • Drug: Enzalutamide
  • Drug: Venetoclax

Other Study ID Numbers

  • I 63418
  • NCI-2018-02448
  • I 63418

Start Date (Actual)

2019-08-02

Primary Completion Date (Actual)

2022-07-18

Study Completion Date (Actual)

2023-08-11

Enrollment (Actual)

10

Study Type

Interventional

Phase

Phase 1